Literature DB >> 19741524

Antifungal drug resistance: do molecular methods provide a way forward?

David S Perlin1.   

Abstract

PURPOSE OF REVIEW: Antifungal drug resistance is a confounding factor that negatively impacts clinical outcome for patients with serious mycoses. Early detection of fungi in blood or other specimens with a rapid assessment of drug susceptibility could improve the survival of patients with invasive disease by accelerating the initiation of appropriate antifungal treatment. Recent years have seen the growth of molecular technology that is ideally suited for fungal identification and assessment of drug resistance mechanisms. RECENT
FINDINGS: Elucidation of the genetic mechanisms responsible for triazole and echinocandin resistance in prominent Candida spp. and Aspergillus spp. provides an opportunity to develop molecular diagnostic platforms suitable for rapid detection of primary and secondary drug resistance. Several highly dynamic and robust amplification/detection methodologies are now available that can provide simultaneous species identification and high fidelity discrimination of resistance alleles.
SUMMARY: Molecular diagnostic platforms are ideal for rapid detection of fungal pathogens and they provide an opportunity to develop in parallel molecular assays that can evaluate antifungal drug resistance.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19741524      PMCID: PMC3913535          DOI: 10.1097/QCO.0b013e3283321ce5

Source DB:  PubMed          Journal:  Curr Opin Infect Dis        ISSN: 0951-7375            Impact factor:   4.915


  76 in total

Review 1.  Diagnosis of fungal infections: current status.

Authors:  David A Stevens
Journal:  J Antimicrob Chemother       Date:  2002-02       Impact factor: 5.790

Review 2.  Diagnosis of fungal infection: new technologies for the mycology laboratory.

Authors:  B D Alexander
Journal:  Transpl Infect Dis       Date:  2002       Impact factor: 2.228

Review 3.  Non-culture based diagnostic tests for mycotic infections.

Authors:  E Reiss; T Obayashi; K Orle; M Yoshida; R M Zancopé-Oliveira
Journal:  Med Mycol       Date:  2000       Impact factor: 4.076

4.  Contribution of mutations in the cytochrome P450 14alpha-demethylase (Erg11p, Cyp51p) to azole resistance in Candida albicans.

Authors:  Patrick Marichal; Luc Koymans; Staf Willemsens; Danny Bellens; Peter Verhasselt; Walter Luyten; Marcel Borgers; Frans C S Ramaekers; Frank C Odds; Hugo Vanden Bossche
Journal:  Microbiology       Date:  1999-10       Impact factor: 2.777

5.  Rapid detection of point mutations by fluorescence resonance energy transfer and probe melting curves in Candida species.

Authors:  J Loeffler; L Hagmeyer; H Hebart; N Henke; U Schumacher; H Einsele
Journal:  Clin Chem       Date:  2000-05       Impact factor: 8.327

6.  International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program.

Authors:  M A Pfaller; D J Diekema; R N Jones; H S Sader; A C Fluit; R J Hollis; S A Messer
Journal:  J Clin Microbiol       Date:  2001-09       Impact factor: 5.948

7.  Development and evaluation of the nuclisens basic kit NASBA for the detection of RNA from Candida species frequently resistant to antifungal drugs.

Authors:  Juergen Loeffler; Christiane Dorn; Holger Hebart; Philipp Cox; Stella Magga; Hermann Einsele
Journal:  Diagn Microbiol Infect Dis       Date:  2003-03       Impact factor: 2.803

8.  Resistance mechanisms in clinical isolates of Candida albicans.

Authors:  Theodore C White; Scott Holleman; Francis Dy; Laurence F Mirels; David A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

9.  Nucleic acid sequence-based amplification of Aspergillus RNA in blood samples.

Authors:  J Loeffler; H Hebart; P Cox; N Flues; U Schumacher; H Einsele
Journal:  J Clin Microbiol       Date:  2001-04       Impact factor: 5.948

10.  The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro.

Authors:  J C Bowman; P Scott Hicks; M B Kurtz; H Rosen; D M Schmatz; P A Liberator; C M Douglas
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191

View more
  31 in total

1.  Use of matrix-assisted laser desorption ionization-time of flight mass spectrometry for caspofungin susceptibility testing of Candida and Aspergillus species.

Authors:  Elena De Carolis; Antonietta Vella; Ada R Florio; Patrizia Posteraro; David S Perlin; Maurizio Sanguinetti; Brunella Posteraro
Journal:  J Clin Microbiol       Date:  2012-04-25       Impact factor: 5.948

2.  Profiling the Aspergillus fumigatus proteome in response to caspofungin.

Authors:  Steven E Cagas; Mohit Raja Jain; Hong Li; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2010-10-25       Impact factor: 5.191

3.  Echinocandin failure case due to a previously unreported FKS1 mutation in Candida krusei.

Authors:  Rasmus Hare Jensen; Ulrik Stenz Justesen; Annika Rewes; David S Perlin; Maiken Cavling Arendrup
Journal:  Antimicrob Agents Chemother       Date:  2014-03-31       Impact factor: 5.191

Review 4.  Echinocandin resistance, susceptibility testing and prophylaxis: implications for patient management.

Authors:  David S Perlin
Journal:  Drugs       Date:  2014-09       Impact factor: 9.546

5.  Update on fungal diagnostics.

Authors:  Allen T Griffin; Kimberly E Hanson
Journal:  Curr Infect Dis Rep       Date:  2014-08       Impact factor: 3.725

Review 6.  Topical antimicrobials for burn wound infections.

Authors:  T Dai; Y Y Huang; S K Sharma; J T Hashmi; D B Kurup; M R Hamblin
Journal:  Recent Pat Antiinfect Drug Discov       Date:  2010-06

7.  Interlaboratory reproducibility of Etest amphotericin B and caspofungin yeast susceptibility testing and comparison with the CLSI method.

Authors:  S Ranque; L Lachaud; M Gari-Toussaint; A Michel-Nguyen; M Mallié; J Gaudart; S Bertout
Journal:  J Clin Microbiol       Date:  2012-05-02       Impact factor: 5.948

8.  Protection from systemic Candida albicans infection by inactivation of the Sts phosphatases.

Authors:  Shamoon Naseem; David Frank; James B Konopka; Nick Carpino
Journal:  Infect Immun       Date:  2014-11-24       Impact factor: 3.441

9.  Use of epidemiological cutoff values to examine 9-year trends in susceptibility of Candida species to anidulafungin, caspofungin, and micafungin.

Authors:  M Pfaller; L Boyken; R Hollis; J Kroeger; S Messer; S Tendolkar; D Diekema
Journal:  J Clin Microbiol       Date:  2010-12-08       Impact factor: 5.948

10.  Quantitative Analysis of Single-Nucleotide Polymorphism for Rapid Detection of TR34/L98H- and TR46/Y121F/T289A-Positive Aspergillus fumigatus Isolates Obtained from Patients in Iran from 2010 to 2014.

Authors:  Faezeh Mohammadi; Seyed Jamal Hashemi; Jan Zoll; Willem J G Melchers; Haleh Rafati; Parvin Dehghan; Sasan Rezaie; Ali Tolooe; Yalda Tamadon; Henrich A van der Lee; Paul E Verweij; Seyedmojtaba Seyedmousavi
Journal:  Antimicrob Agents Chemother       Date:  2015-11-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.